drugset / Trial / NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2023-05-23
- Primary completion
- 2027-04-01
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | FOG-001 | Unknown | — | Intravenous |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Trifluridine/tipiracil | Unknown | — | — |
| Subject | fluorouracil | Small molecule | — | — |